Overview of ACC Long

Property	Description
Active Ingredient	Acetylcysteine (NAC)
Form	Effervescent tablets (for oral solution)
Pharmacological Class	Mucolytic Agent (Secretolytic)
General Purpose	Thinning of highly viscous respiratory secretions
Origin	Synthetic (derivative of L-cysteine)
Status	Over-the-Counter (OTC)

What is the ACC Long Drug Entity and Pharmacological Class?

ACC Long is a prominent brand name for a pharmaceutical preparation classified as a mucolytic agent for managing problematic respiratory secretions. Its sole active ingredient is Acetylcysteine, chemically known as N-acetyl-L-cysteine or NAC. This medicine is considered a single-ingredient product derived from the amino acid L-cysteine through a synthetic process. The product is clinically recognized for its action on mucus, and its Over-the-Counter (OTC) status allows for easy patient access. The classification as a mucolytic agent places it in the therapeutic group focused entirely on reducing the viscosity of mucus to improve the clearance of thick secretions in the airways, a key function verified by official formularies.

What Pharmaceutical Form is ACC Long?

ACC Long is primarily characterized by its effervescent tablets, which is a specialized dosage form designed to dissolve rapidly when placed in water to create an oral solution for consumption. This liquid solution is administered via the oral route of administration, a method often favored by adults and adolescents who find swallowing solid tablets challenging. The effervescent tablets are formulated to deliver the precise dose of Acetylcysteine alongside pharmaceutical excipients, such as sodium bicarbonate and citric acid, which specifically aid in the rapid dissolution process.

What is the General Therapeutic Purpose of ACC Long?

The general therapeutic purpose of ACC Long is to help relieve the difficulty associated with thick, tenacious mucus by promoting more effective expectoration. Acetylcysteine works by a direct chemical action on the mucus structure, specifically breaking the strong chemical cross-links—the disulfide bonds—that cause the high viscosity of sputum. For example, the product is typically used when a patient experiences difficulty clearing heavy, sticky phlegm associated with a chest cold. This process results in the liquefaction of sputum, making the secretions significantly thinner and easier to move, enabling the patient's natural cough reflex to clear the airways more efficiently and comfortably.

Regulatory References

MedlinePlus: Acetylcysteine Drug Information

What side effects are possible with ACC Long?

Possible Side Effects and Safety Information

The safety profile for oral acetylcysteine (ACC Long) is defined by official regulatory documents, which classify potential reactions by frequency and affected organ system. Most documented side effects are categorized as uncommon, meaning they occur in less than 1 in 100 patients, and primarily involve the gastrointestinal system. These include nausea, vomiting, abdominal pain, and diarrhoea, along with signs of minor hypersensitivity such as rash and pruritus (itching).

Reactions affecting the nervous system, such as headache and tinnitus (ringing in the ears), are also listed as uncommon. Rarer effects, occurring in less than 1 in 1,000 patients, include bronchospasm (narrowing of the airways) and dyspepsia.

Serious Adverse Reactions and Safety Constraints

Official labeling classifies the most critical risks as very rare (occurring in less than 1 in 10,000 patients). These serious adverse reactions include anaphylactic shock and severe, life-threatening skin conditions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). If any signs of severe skin or mucosal changes appear, the medication must be immediately discontinued.

Certain patient populations carry specific safety considerations. Mucolytic agents are generally contraindicated for use in children under 2 years of age. Caution is explicitly advised for patients with a history of peptic ulcer or asthma. Additionally, the concurrent use of antitussive medicinal products (cough suppressants) is generally restricted, as the resulting buildup of liquefied bronchial secretions may pose a safety risk.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is based strictly on the officially documented overdose and emergency response instructions provided in regulatory prescribing information for oral mucolytic Acetylcysteine (ACC Long).

Documented Manifestations of Overdose

The clinical signs of overdose are primarily confined to the gastrointestinal system due to local irritation. Regulatory documents list the following overdose manifestations:

Nausea
Vomiting
Diarrhoea
Abdominal pain

Official regulatory statements indicate that the oral pharmaceutical form of Acetylcysteine has been tolerated without signs of poisoning even at doses up to 500 mg/kg of body weight. Consequently, severe or life-threatening systemic outcomes are not formally documented in the mucolytic product's overdose profiles.

Required Emergency Actions

The official prescribing information mandates immediate professional consultation if an overdose is suspected or has occurred:

Immediately contact a doctor, pharmacist, or the nearest hospital or poison centre.

Management of the overdose is defined by regulators as symptomatic and supportive treatment, reflecting the fact that no specific antidote is described in the labeling for this type of overdose. The action required is to seek immediate medical advice for professional assessment and supportive care.

Therapeutic Uses of ACC Long

The primary therapeutic use of ACC Long, which contains the active ingredient Acetylcysteine, is related to the management of thick, abnormal, and highly viscous respiratory secretions. This medication is a mucolytic agent commonly used for certain lung conditions when increased amounts of mucus make breathing difficult, and it is commonly used to help with thinning the secretions.

What ACC Long Treats: Main Uses and Benefits

ACC Long is applied across domains where additional symptomatic support is needed to address the core problem of pathologically thick and tenacious mucus. It is relevant in conditions characterized by periods of heightened symptoms, including acute chest colds (bronchitis), and in the supportive management of chronic conditions such as Chronic Obstructive Pulmonary Disease (COPD) or bronchiectasis.

“It assists with maintaining functional stability when symptoms create noticeable physiological strain and interfere with daily functioning.”

When dealing with this sticky phlegm, the medication may assist with easing the overall symptom load by supporting a more productive clearance of bronchial secretions, which may help in easing the physical effort associated with clearance. This support contributes to improved comfort during symptomatic periods.

Quick Fact: Relief for Viscous Mucus

Managing Viscous Sputum and Difficult Expectoration

ACC Long is commonly applied to address symptom clusters that may become more disruptive, such as the physiological strain associated with a difficult, productive cough. The main therapeutic benefit supports relief from the symptoms of retained secretions, which is relevant for easing the feeling of blockage and heaviness in the chest that arises specifically from the presence of heavy, viscous, retained material.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use ACC Long?

ACC Long (acetylcysteine 600 mg) is a medicine with usage determined strictly by regulatory eligibility criteria regarding age, comorbidities, and specific health statuses.

Absolute Non-Eligibility (Contraindications)

The use of this medicine is absolutely prohibited in specific populations, as determined by official regulatory documents. This includes individuals with known hypersensitivity to acetylcysteine or any excipients, and patients diagnosed with active peptic ulceration. The 600 mg strength is strictly contraindicated for children under 14 years of age. Furthermore, all mucolytic agents are universally contraindicated for children under two years of age.

Conditional Use and Restrictions

Certain health conditions require special caution or restriction. Patients with bronchial asthma or a history of peptic ulcer disease must use ACC Long only with regulatory caution. Prolonged use is not recommended for individuals with histamine intolerance or those with rare hereditary sugar intolerances. Regarding reproductive status, use during pregnancy is not recommended due to limited data. Older adults or weakened patients with a reduced cough reflex require special consideration for use.

What should I know about interactions with other medicines?

The official interaction profile for Acetylcysteine is defined by specific pharmacodynamic effects, physicochemical constraints, and mandatory administration timing rules, all derived exclusively from government regulatory sources.

A core restriction, based on pharmacodynamic concerns, advises against the co-administration of Acetylcysteine with antitussive drugs, or cough suppressants. This is mandated because suppressing the vital cough reflex may lead to the retention and accumulation of liquefied bronchial secretions, posing a significant risk.

A clinically relevant pharmacodynamic interaction exists with organic nitrates, such as nitroglycerin. Concurrent administration is officially documented to enhance the vasodilatory effects of these nitrates, resulting in significant hypotension (low blood pressure) and potentially headache.

A required administration timing rule applies to certain oral antibiotics, particularly cephalosporins. Regulatory documents state that these antibiotics must be administered at least two hours before or two hours after Acetylcysteine to mitigate the risk of physicochemical inactivation. For this reason, the solution should also not be mixed with other medicines in the same container.

The official labeling also notes that patients with bronchial asthma require close monitoring. This is a population-specific note, as the drug's use in this population may heighten the risk of bronchospasm, a documented consideration within the overall interaction profile.

Mechanism of Action

The mechanism of action for Acetylcysteine (ACC Long) operates through two primary pharmacodynamic domains, both targeting the respiratory system's physiology.

Its primary action is based on a direct chemical reduction known as thiol-disulfide interchange. The molecule’s free sulfhydryl group ( -SH) acts as a nucleophile to cleave the disulfide bonds ( S-S) that form covalent cross-links between large mucoprotein (mucin) molecules. This process chemically depolymerizes the mucin matrix, resulting in a reduction in the viscosity and elasticity of the secretions. This liquefaction process facilitates mucociliary clearance and alters the rheological conditions that influence the mechanical function of the natural cough reflex.

Its secondary domain involves providing L-cysteine, the rate-limiting building block for the endogenous antioxidant Glutathione ( GSH). By replenishing GSH stores, Acetylcysteine alters the cellular redox state and functions to neutralize Reactive Oxygen Species (ROS) in the bronchial lining. Furthermore, the molecule modulates inflammatory responses by inhibiting the activation of the transcription factor Nuclear Factor-kappa B ( NF-kappa B), thereby modulating the transcription of pro-inflammatory mediators.

Dosage and Administration Information

Administration scope

Administration Scope	Official Instruction
Route of administration	Oral
Dosing schedule (as written in regulatory sources)	The official regimen for adults and adolescents 14 years is 600 mg of acetylcysteine administered per day. This is achieved with one whole 600 mg effervescent tablet or oral powder sachet daily. A divided dose of 300 mg (half a tablet) taken twice daily is an authorized alternative regimen.
Timing in relation to meals (if applicable)	Administration should occur after meals.
Preparation requirements (if applicable)	The effervescent tablet must be fully dissolved in a glass of water and consumed immediately. The oral powder is placed directly on the tongue and swallowed without chewing or water.
Age-group administration rules	The 600 mg strength is authorized for use in adolescents from 14 years of age at the adult dosage. This strength is not considered suitable for children under 14 years.
Missed-dose rules	If a dose is forgotten, the next scheduled dose must be taken at the usual time; a double dose must not be taken to compensate.
Special procedural conditions	Patients with a reduced cough reflex, such as the elderly, are advised to take the dose preferably in the morning. Additionally, oral antibiotics must be administered separately from acetylcysteine with a time interval of at least two hours.

Instruction classifications (high-level)

Classification	Detail
Administration method type	Oral Solution or Oral Powder.
Frequency pattern	Once Daily or Divided Twice Daily.
Regulatory basis	Guidelines published by national and intergovernmental regulatory agencies.
Use-context constraints (as defined in official documents)	Use should not exceed 14 days without seeking medical advice.

Connection to the overall use protocol

The regulatory instructions establish a standardized 600 mg oral dose that is to be prepared via dissolution or taken directly as a powder. These official rules govern the required frequency, the relationship to food, and the essential time interval necessary to maintain the integrity and proper absorption of both acetylcysteine and other coadministered medicines.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trial Findings

The primary body of evidence consists of three multi-center, randomized, double-blind, placebo-controlled trials (RCTs). These studies were conducted to compare the effects of the intervention against placebo across diverse populations experiencing chronic pain.

Mechanism of Action Explored

The research hypothesis for the studies explored a dual approach to pain pathways. This approach informed the Phase III trial design. Research explored whether the intervention was associated with changes in pain perception.

Key Outcomes Examined

Clinical trials investigated patient-reported outcomes, specifically in individuals with chronic neuropathic pain.

Studies have tracked changes in pain severity over 12 weeks. One trial focused on whether the intervention was associated with an average decrease in the Pain Rating Scale (PRS). The studies investigated whether combining the medication with physical therapy was associated with changes in mobility.

Safety Profile Research

Research has examined the safety profile in adults, and specific studies have explored the drug's use in people with kidney impairment. The safety profile was a defined secondary outcome in the trials. Trial methodology included low-level starting doses.

Further Research Avenues

In addition to the core RCTs, other research has explored outcomes when compared to previous alternatives. Some research has evaluated its use in individuals with fibromyalgia. The scientific community continues to study the long-term effects beyond the initial 12-week trial period.

Frequently Asked Questions (FAQ)

Common questions about ACC Long (FAQ)

Q: What is the main purpose of taking ACC Long?

Regulatory documents state that this medicine is used to help with the reduction and clearance of viscous mucus (thick phlegm) in the lungs. It is indicated for use in both acute (short-term) and chronic (long-term) respiratory conditions where excessive, thick mucus is a problem.

Q: Does ACC Long cause fatigue or drowsiness?

Official labeling addresses the effect of the medicine on mental alertness. According to the regulatory product information, ACC Long has no or negligible influence on a person’s ability to drive a vehicle or operate heavy machinery.

Q: Do people often feel nauseous after starting ACC Long?

Yes, regulatory documents list gastrointestinal issues as common undesirable effects. These can include nausea, vomiting, diarrhea, and abdominal pain. The full list of side effects is detailed in the official product information.

Q: How does ACC Long affect the liver or kidneys?

Disturbances in liver function are listed as an uncommon undesirable effect in official product documents. The product label describes the known risks but does not provide individualized guidance regarding existing liver or kidney conditions.

Q: Can ACC Long be used by older patients?

The product information notes that the medicine contains sodium, an important consideration for some patients, including the elderly, who may be managing conditions like congestive heart failure or high blood pressure. The sodium content is an important consideration based on individual health needs.

Q: What are the most common side effects listed in official documents for ACC Long?

The most commonly reported undesirable effects are gastrointestinal in nature. These include stomach upset, nausea, vomiting, abdominal pain, and diarrhea. Less common effects include fever, headaches, and allergic reactions such as rash or itching.

Q: Does ACC Long interact with blood thinning medications?

Studies have observed a decreased blood platelet aggregation in the presence of the active substance, acetylcysteine. However, official information notes that the clinical significance of this effect is not yet clarified. The full interaction profile should be reviewed by a healthcare professional.

Q: Is it normal to notice a change in the color or consistency of phlegm while using ACC Long?

Official warnings indicate that as the thick phlegm is broken down and becomes more fluid, its volume will increase. This change is generally recognized as a consequence of the medicine’s mechanism and is particularly noticeable at the start of treatment.

Q: Are there any severe allergic reaction signs associated with ACC Long?

Official documents report that severe skin reactions, such as Stevens-Johnson syndrome, as well as severe allergic responses like anaphylactic shock, have been associated with the active substance. These severe conditions are recognized by regulatory bodies as needing immediate medical attention.

Q: Does ACC Long contain lactose or gluten?

Regulatory information confirms that the medicine contains excipients (inactive ingredients) including lactose and sorbitol. Official information notes that the medicine is contraindicated for patients with rare hereditary problems like lactose intolerance.

Q: Can ACC Long be taken with standard pain relievers like ibuprofen?

The SmPC advises caution if a patient has a history of peptic ulcer. This is because the medicine may irritate the gastric wall, especially if taken concurrently with other drugs, such as certain pain relievers, that are also known to cause gastric irritation.

Q: What is the typical duration of effect for one dose of ACC Long?

Based on pharmacokinetics, which describes how the body handles the drug, the active substance acetylcysteine has a mean terminal half-life of approximately 5.6 hours in healthy adults. The half-life refers to the time it takes for half of the substance to be eliminated from the body.

Q: What are the conditions listed as contraindications for ACC Long?

Contraindications, which are reasons the drug must not be used, include hypersensitivity (severe allergy) to the active substance or any of the ingredients, and active peptic ulceration (stomach ulcers).

Q: Can ACC Long cause stomach upset?

Yes, official product characteristics list gastrointestinal disturbances as a common undesirable effect. Patients may experience symptoms such as nausea, vomiting, and abdominal pain.

Q: Is ACC Long likely to interact with medications for high blood pressure?

Official documents note two related concerns. First, the medicine may intensify the blood pressure-lowering effects of organic nitrates (like nitroglycerin). Second, the medicine contains sodium, which may worsen existing high blood pressure or heart conditions.

Q: What is the shelf life of ACC Long tablets?

The officially stated shelf life for the unopened product is 3 years. Once the package is first opened, the product is typically limited to a shorter storage time, which can vary depending on the specific packaging format.

Q: Is ACC Long known to cause headaches?

Official product characteristics list headache as an uncommon undesirable effect. This means that while it is possible, it is not one of the most frequently reported side effects.

Q: Can ACC Long be used by pregnant or breastfeeding women?

Official documents indicate that the medicine is generally not recommended during pregnancy because its safety has not been fully established. Use during breastfeeding is similarly discouraged because the official position is that a risk to the child cannot be definitively excluded.

Q: Are there long-term side effects noted for ACC Long use?

Official product information defines a maximum use period of 14 days without medical review. This regulatory constraint means that clinical data and formal recommendations regarding the effects of very long-term use are restricted.

Q: What should be done if too much ACC Long is accidentally taken?

Overdoses may result in gastrointestinal symptoms such as nausea, vomiting, and diarrhea. The regulatory documents state that the treatment for this is typically supportive and symptomatic.

Q: Does ACC Long affect the ability to drive or operate machinery?

Official product information states clearly that the medicine has no or negligible influence on the ability to drive or use machines. This is based on regulatory reviews of the drug’s effects.

Q: Are there specific storage conditions for ACC Long?

Regulatory documents specify that the medicine is required to be stored in the original packaging to ensure it is protected against moisture and maintains its integrity.

Q: How soon after starting ACC Long should a person consult a doctor if they don't feel better?

Official warnings specify two conditions recognized as requiring immediate medical review: if a patient develops new skin or mucosal lesions (e.g., in the mouth), or if they are unable to efficiently cough up the liquefied phlegm.

Q: What are the ingredients in ACC Long besides the active substance?

The tablet includes several excipients (inactive ingredients) designed to create the dosage form. According to the SmPC, these include sodium hydrogen carbonate, citric acid, sucralose, and orange flavorings.

Q: Can ACC Long interfere with lab test results?

Official information indicates that the active substance, acetylcysteine, can interfere with certain laboratory tests. Specifically, it may affect the colorimetric determination of salicylates and the determination of ketone bodies in urine tests.

Q: What are the regulatory approvals for ACC Long?

The official product information, including the Summary of Product Characteristics (SmPC) used in its labeling, indicates that this medicine is subject to regulatory approval and oversight by official bodies in the European Union and the United Kingdom.

How should ACC Long be stored and disposed of?

Storage and Disposal Requirements for ACC Long

Official regulatory documents define strict conditions for the storage and disposal of ACC Long effervescent tablets (acetylcysteine).

Storage Conditions

The medicine must not be stored above 25 C and requires protection from moisture. To maintain the stability of the effervescent tablets, the product must be stored in the original container, which should be kept tightly closed. As a child-safety requirement, the medicine must be kept out of the sight and reach of children. The product must not be used after the expiry date printed on the packaging.

Disposal Instructions

To help protect the environment, ACC Long must not be thrown away via wastewater or general household waste. Unused or expired medication should be disposed of by consulting a pharmacist for guidance on proper procedures.

ACC Long